Functionalized scaffold-mediated interleukin 10 gene delivery significantly improves survival rates of stem cells in vivo

Molecular Therapy

Volumn 19, Issue 5, 2011, Pages 969-978

  Holladay, Carolyn ^a   Power, Karen ^b   Sefton, Michael ^c   O'Brien, Timothy ^a   Gallagher, William M ^b   Pandit, Abhay ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; COLLAGEN; INTERLEUKIN 10; INTERLEUKIN 5; MOLECULAR SCAFFOLD; POLYMER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; MESENCHYMAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPTIMAL DRUG DOSE; PHENOTYPE; QUALITATIVE ANALYSIS; RAT; STEREOLOGY; SURVIVAL RATE;

RATTUS;

EID: 79955617122     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.311     Document Type: Article

References (50)

1. Lachmann, N and Nikol, S (2007). Therapeutic angiogenesis for peripheral artery disease: stem cell therapy. VASA 36: 241-251. (Pubitemid 350260418)
2. Abe, K (2000). Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J Cereb Blood Flow Metab 20: 1393-1408.
3. Locatelli, F, Bersano, A, Ballabio, E, Lanfranconi, S, Papadimitriou, D, Strazzer, S et al. (2009). Stem cell therapy in stroke. Cell Mol Life Sci 66: 757-772.
4. Urbaniak Hunter, K, Yarbrough, C and Ciacci, J (2010). Stem cells in the treatment of stroke. Adv Exp Med Biol 671: 105-116.
5. Lindvall, O and Kokaia, Z (2010). Stem cells in human neurodegenerative disorders- time for clinical translation? J Clin Invest 120: 29-40.
6. Nowak, R (1994). New cell transplants may mend a broken heart. Science 264: 31. (Pubitemid 24144488)
7. Leri, A, Kajstura, J, Anversa, P and Frishman, WH (2008). Myocardial regeneration and stem cell repair. Curr Probl Cardiol 33: 91-153. (Pubitemid 351163350)
8. Herrmann, JL, Abarbanell, AM, Weil, BR, Wang, Y, Wang, M, Tan, J et al. (2009). Cell-based therapy for ischemic heart disease: a clinical update. Ann Thorac Surg 88: 1714-1722.
9. Orlic, D, Kajstura, J, Chimenti, S, Jakoniuk, I, Anderson, SM, Li, B et al. (2001). Bone marrow cells regenerate infarcted myocardium. Nature 410: 701-705. (Pubitemid 32290358)
10. Delcarpio, JB and Claycomb, WC (1995). Cardiomyocyte transfer into the mammalian heart - cell-to-cell interactions in-vivo and in-vitro. In: Claycomb, WC, DiNardo, P (eds). Cardiac Growth and Regeneration, vol. 752. New York Academy of Sciences: New York, pp 267-285.
11. Christlieb, IY (1996). Cellular cardiomyoplasty. Ann Thorac Surg 61: 772-773.
12. Li, RK, Mickle, DA, Weisel, RD, Zhang, J and Mohabeer, MK (1996). In vivo survival and function of transplanted rat cardiomyocytes. Circ Res 78: 283-288. (Pubitemid 26040857)
13. Nyolczas, N, Gyöngyösi, M, Beran, G, Dettke, M, Graf, S, Sochor, H et al. (2007). Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction. Am Heart J 153: 212. e1-212.e7.
14. Solheim, S, Seljeflot, I, Lunde, K, Aukrust, P, Yndestad, A, Grøgaard, HK et al. (2008). Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction. Am Heart J 155: 55. e1-55.e9.
15. Beitnes, JO, Hopp, E, Lunde, K, Solheim, S, Arnesen, H, Brinchmann, JE et al. (2009). Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart 95: 1983-1989.
16. Schächinger, V, Erbs, S, Elsässer, A, Haberbosch, W, Hambrecht, R, Hölschermann, H et al.; REPAIR-AMI Investigators. (2006). Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210-1221. (Pubitemid 44427445)
17. Zeiher, AM, Schachinger, V and Dimmeler, S (2007). Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial: reply. Eur Heart J; 28: 2173-2174. (Pubitemid 47517443)
18. Ripa, RS and Kastrup, J (2009). Stem cells: REGENT trial-the end of cell therapy for MI? Nat Rev Cardiol 6: 567-568.
19. Tendera, M, Wojakowski, W, Ruzyllo, W, Chojnowska, L, Kepka, C, Tracz, W et al.; REGENT Investigators. (2009). Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 30: 1313-1321.
20. Meyer, GP, Wollert, KC, Lotz, J, Pirr, J, Rager, U, Lippolt, P et al. (2009). Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 30: 2978-2984.
21. Pons, J, Huang, Y, Takagawa, J, Arakawa-Hoyt, J, Ye, J, Grossman, W et al. (2009). Combining angiogenic gene and stem cell therapies for myocardial infarction. J Gene Med 11: 743-753.
22. Egdell, RM, Siminiak, T and Sheridan, DJ (1994). Modulation of neutrophil activity by nitric oxide during acute myocardial ischaemia and reperfusion. Basic Res Cardiol 89: 499-509.
23. Suzuki, K, Sawa, Y, Kaneda, Y, Ichikawa, H, Shirakura, R and Matsuda, H (1997). In vivo gene transfection with heat shock protein 70 enhances myocardial tolerance to ischemia-reperfusion injury in rat. J Clin Invest 99: 1645-1650. (Pubitemid 27163815)
24. Yang, Z, Zingarelli, B and Szabó, C (2000). Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation 101: 1019-1026. (Pubitemid 30131705)
25. Kaur, K, Dhingra, S, Slezak, J, Sharma, AK, Bajaj, A and Singal, PK (2009). Biology of TNFalpha and IL-10, and their imbalance in heart failure. Heart Fail Rev 14: 113-123.
26. Karpiński, L, Płaksej, R, Kosmala, W and Witkowska, M (2008). Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiol Pol 66: 1279-1285.
27. Fujisaka, S, Usui, I, Bukhari, A, Ikutani, M, Oya, T, Kanatani, Y et al. (2009). Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58: 2574-2582.
28. Bourlier, V and Bouloumie, A (2009). Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab 35: 251-260.
29. van Exel, E, Gussekloo, J, de Craen, AJ, Frölich, M, Bootsma-Van Der Wiel, A and Westendorp, RG; Leiden 85 Plus Study (2002). Low production capacity of interleukin- 10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 51: 1088-1092. (Pubitemid 34438354)
30. Batteux, F, Trebeden, H, Charreire, J and Chiocchia, G (1999). Curative treatment of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for interleukin-10. Eur J Immunol 29: 958-963. (Pubitemid 29119076)
31. Lee, M, Park, H, Youn, J, Oh, ET, Ko, K, Kim, S et al (2006). Interleukin-10 plasmid construction and delivery for the prevention of type 1 diabetes. Immunology of Diabetes IV: Progress in Our Understanding, vol. 1079. Blackwell Publishing: Oxford, pp 313-319. (Pubitemid 44968740)
32. Cox, G (1996). IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Am J Physiol Lung Cell Mol Physiol; 15: L566-L571.
33. Palaniyandi, SS, Watanabe, K, Ma, M, Tachikawa, H, Kodama, M and Aizawa, Y (2004). Inhibition of mast cells by interleukin-10 gene transfer contributes to protection against acute myocarditis in rats. Eur J Immunol 34: 3508-3515. (Pubitemid 40012168)
34. Burchfield, JS, Iwasaki, M, Koyanagi, M, Urbich, C, Rosenthal, N, Zeiher, AM et al. (2008). Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res 103: 203-211.
35. Stumpf, C, Seybold, K, Petzi, S, Wasmeier, G, Raaz, D, Yilmaz, A et al. (2008). Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail 10: 733-739.
36. Ooboshi, H, Ibayashi, S, Shichita, T, Kumai, Y, Takada, J, Ago, T et al. (2005). Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 111: 913-919. (Pubitemid 40279894)
37. Hong, YS, Laks, H, Cui, G, Chong, T and Sen, L (2002). Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant 21: 1188-1200. (Pubitemid 35300465)
38. Dudler, J, Li, J, Pagnotta, M, Pascual, M, von Segesser, LK and Vassalli, G (2006). Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation 82: 1733-1737. (Pubitemid 46035660)
39. Sandovici, M, Deelman, LE, de Zeeuw, D, van Goor, H and Henning, RH (2008). Immune modulation and graft protection by gene therapy in kidney transplantation. Eur J Pharmacol 585: 261-269.
40. Holladay, CA, O'Brien, T and Pandit, A (2010). Non-viral gene therapy for myocardial engineering. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2: 232-248.
41. Holladay, C, Keeney, M, Greiser, U, Murphy, M, O'Brien, T and Pandit, A (2009). A matrix reservoir for improved control of non-viral gene delivery. J Control Release 136: 220-225.
42. Moore, KW, de Waal Malefyt, R, Coffman, RL and O'Garra, A (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765. (Pubitemid 32368050)
43. Manning, E, Pham, S, Li, S, Vazquez-Padron, RI, Mathew, J, Ruiz, P et al. (2010). Interleukin-10 delivery via mesenchymal stem cells: a novel gene therapy approach to prevent lung ischemia-reperfusion injury. Hum Gene Ther 21: 713-727.
44. van Putten, SM, Wübben, M, Hennink, WE, van Luyn, MJ and Harmsen, MC (2009). The downmodulation of the foreign body reaction by cytomegalovirus encoded interleukin-10. Biomaterials 30: 730-735.
45. Tanaka, F, Tominaga, K, Shiota, M, Ochi, M, Kuwamura, H, Tanigawa, T et al. (2008). Interleukin-10 gene transfer to peritoneal mesothelial cells suppresses peritoneal dissemination of gastric cancer cells due to a persistently high concentration in the peritoneal cavity. Cancer Gene Ther 15: 51-59. (Pubitemid 350261300)
46. Nauta, AJ, Westerhuis, G, Kruisselbrink, AB, Lurvink, EG, Willemze, R and Fibbe, WE (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-2120. (Pubitemid 44395028)
47. Zhang, G, Wang, X, Wang, Z, Zhang, J and Suggs, L (2006). A PEGylated fibrin patch for mesenchymal stem cell delivery. Tissue Eng 12: 9-19.
48. Mosser, DM and Edwards, JP (2008). Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
49. Brown, BN, Valentin, JE, Stewart-Akers, AM, McCabe, GP and Badylak, SF (2009). Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 30: 1482-1491.
50. Breen, AM, Dockery, P, O'Brien, T and Pandit, AS (2008). The use of therapeutic gene eNOS delivered via a fibrin scaffold enhances wound healing in a compromised wound model. Biomaterials 29: 3143-3151.